drugset / Trial / NCT04922450
Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
In this single-arm study, pathologically confirmed advanced head and neck squamous cell carcinoma will be enrolled to investigate the efficacy and safety of Camrelizumab in combination With albumin paclitaxel and cisplatin.
Timeline
- Start
- 2021-01-20
- Primary completion
- 2023-01-20
- Completion
- 2023-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin paclitaxel | Unknown | 260 mg/m2 | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |